Compare UFG & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFG | FGEN |
|---|---|---|
| Founded | 2021 | 1993 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.1M | 35.6M |
| IPO Year | 2025 | 2014 |
| Metric | UFG | FGEN |
|---|---|---|
| Price | $0.99 | $9.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $146.50 |
| AVG Volume (30 Days) | ★ 273.6K | 26.2K |
| Earning Date | 10-28-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.01 | ★ 53.38 |
| Revenue | ★ $195,620,824.00 | $8,298,000.00 |
| Revenue This Year | $41.40 | N/A |
| Revenue Next Year | $25.00 | N/A |
| P/E Ratio | $172.99 | ★ $0.16 |
| Revenue Growth | ★ 49.71 | N/A |
| 52 Week Low | $0.66 | $4.85 |
| 52 Week High | $11.00 | $21.94 |
| Indicator | UFG | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 57.91 |
| Support Level | $0.75 | $8.37 |
| Resistance Level | $1.15 | $9.09 |
| Average True Range (ATR) | 0.10 | 0.45 |
| MACD | 0.07 | 0.17 |
| Stochastic Oscillator | 66.57 | 84.46 |
Uni-Fuels Holdings Ltd is a service provider of marine fuels solutions. The company market, resell and brokers marine fuels products such as VLSFO, HSFO, and MGO. It offers these products to shipping companies and marine fuels suppliers in-port and offshore. In addition, the company may from time to time provide shipping-related services to its customers including but not limited to the arrangement of ship agents, ship provisions and marine fuels surveyors. It operates an integrated business model where It serves its customers through two operating models, sales of marine fuels solutions and brokerage.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.